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Abstract 
Qualitative detection of antibody to hepatitis B virus core antigen (anti-HBc) is an 
important aid in diagnosis of acute, chronic, or resolved HBV infection in conjunction 
with other lab results and clinical information. A multi-center prospective study was 
conducted to validate the performance of the AxSYM CORE 2.0 assay in a diagnostic 
population by evaluating precision and performing method comparison. AxSYM CORE 
2.0 is a competitive microparticle enzyme immunoassay (MEIA) for use on the AxSYM 
system for the qualitative detection of anti-HBc in human adult and pediatric serum or 
plasma. 
A multi-center prospective study was conducted to validate the performance of the 
HbsAg and HbsAg Confirmatory assays in a diagnostic population. Assay performance 
was measured by evaluating precision and performing method comparison. Qualitative 
detection and confinnation of hepatitis B surface antigen (HbsAg) is an important aid in 
diagnosis of HBV infection. The HbsAg and HbsAg Confirmatory assays are 
chemiluminescent microparticle immunoassays for the qualitative detection and 
confirmation ofHbsAg in human adult. 
There are about 350 million chronic hepatitis B virus (HBV) carriers worldwide. A 
proactive approach to the management of this disease is likely to reduce the morbidity 
and mortality caused by HBV. This study aimed to approach the HB core test as a 
screening tool in blood bank. The test is designed to rapidly and accurately detect both 
the HBV surface antigen (HBsAg) and the HBV e antigen (HB Core). A cohort of316 
subjects was tested. The serum clinical sensitivity of the hepatitis B sAg or Hb core test 
was 99.75 and 96.37% for HBsAg and HB Core, respectively. Serum clinical specificity 
was 99.32% for HBsAg and 98.99% for HB core. Analytical sensitivity was satisfactory 
for the purposes of population screening. Visual evaluation showed that the test signals 
were stable for at least 3 h after the recommended evaluation time. No interference or 
cross-reactivity was observed with known interfering substances and virologic markers. 
These results indicate that the hepatitis B sAg/ core test is well suited to the accurate 
detection of HBV carriers. In addition to the good clinical specificity and sensitivity of 
this test, its stability and user-friendly design mean that a correct performance, even under 
field conditions, is highly likely. Consequently, the hepatitis B sAg/core test has the 
potential to identify subjects who require HBV vaccination (HBsAg- and HBeAg-) and 
HBV -infected individuals who might benefit most from antiviral therapy (HBsAg + and 
HBeAgl. 
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1.1 Hepatitis B 
Hepatitis B is one of the three most common types of viral hepatitis, along with hepatitis 
A and C. The Centers for Disease Control and Prevention (CDC) estimates that some 
150,000-300,000 people in the U.S. are newly infected with the hepatitis B virus (HBV) 
each year, and that over 1 million people currently carry the virus. HBV incidence in the 
U.S. has decreased since 1982, when an effective vaccine became available. Chronic 
hepatitis B - like hepatitis C - can cause serious long-tenn liver damage. However, most 
people who are infected with HBV recover completely, and most chronic HBV carriers 
live healthy, mostly symptom-free lives. 
1.2 Hepatitis B virus in blood bank 
The risk of transfusion-transmitted hepatitis B virus (HBV) infection has been reduced by 
screening all blood donations for HBV surface antigen (HBsAg) since 1970. It was 
generally a~cepted that the disappearance ofHBsAg indicates the clearance ofHBV. The 
safety of blood products is one of the major issues in the area of transfusion medicine. 
Transmission of hepatitis B virus (HBV) infection through donated blood is more 
common than hepatitis C virus (HCV) infection (1:60000 vs. 1:103000) . In spite of 
availability of sensitive screening assay for detection of hepatitis B virus surface antigen 
(HBsAg), occasional cases of post-transfusion hepatitis B virus infection (PTH) are 
common. There are three possible explanations for false negative results in commercial 
assays. Blood donors infected with HBsAg mutants and those circulating low level of 
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viral protein may escape detection by screening assay and therefore, may affect the safety 
of blood supply. 
Another explanation is that virus variants yield sequences that are not recognized by the 
antibodies employed in the assays. There are variants in other parts of the genome that 
down regulate the production of HBsAg. Occasionally, a superinfection with hepatitis C 
virus (HCV) may induce clearance of hepatitis B. This could be due to the dominant role 
of HCV in eliciting an immune response. Antibodies to hepatitis B core (HBc) antigen 
are marker of acute, chronic, or resolved HBV infection and remain detectable for life. 
These can be present in the absence of both HBsAg and anti-HBs antibodies, during the 
convalescent period following acute hepatitis B before the appearance of anti-HBs 
antibodies, or in patients who resolved infection but lost detectable anti-HBs antibodies. 
Anti-HBc is therefore detected in anyone who has been infected with HBV. 
It has been demonstrated that some HBsAg negative individuals and those positives for 
anti-HBc continue to replicate HBV. These findings suggest that recovery from acute 
hepatitis B virus infection may not result in complete virus elimination, but rather the 
immune system keeps the virus at a very low level. A positive correlation has been shown 
between anti-HBc titre and detection ofHBV-DNA in serum samples ofHBsAg negative 
individual. 
Currently, a number of countries, including United States screen all donations for anti 
HBc, which is not mandatory in some other countries. However, detection of HBV -DNA 
by polymerase chain reaction (PCR) has the same significance as detection of HBsAg, 
and indicates current HBV infection. All blood donations in Iran are collected from 
healthy donors, and tested for HBsAg as a marker of transmissible HBV. Though these 
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measures have resulted tn low rates of transmission by transfusion but have not 
eliminated it fully. 
Despite the availability of an effective vaccine, HBV infection continues to be an 
important problem in Iran and nearly 8000 to 10000 deaths occur each year due to this 
sequelae. In Iran, the rate of asymptomatic hepatitis B carriers (HBsAg positive) varies 
between 0 and 3.9 per cent with an average of 1. 7 per cent. The prevalence of HBV 
carriers in asymptomatic healthy blood donor in Fars province; the southwest of Iran was 
about 1 per cent. In a study on 4930 healthy blood donors in Hamadan province in Iran, 
5.1 per cent were only positive for anti-HBc, without any detectable HBsAg, but the 
presence ofHBV-DNA has not been determined in this study. 
1.3 Transmission and Prevention 
Hepatitis B (previously known as serum hepatitis) is caused by the hepatitis B virus 
(HBV); a member of the hepadnaviridae family that replicates (multiplies) in liver cells. 
Although the routes of transmission, symptoms, and long-term effects of hepatitis B and 
hepatitis C are similar in many respects, the diseases are caused by two distinct viruses 
that are not closely related. 
Like the hepatitis C virus (HCV), HBV is a blood-borne virus. It can be transmitted by 
sharing drug paraphernalia that comes into contact with blood, including needles, 
syringes, and other injection equipment (e.g., cookers, cottons), cocaine straws, and crack 
pipes. Use only new needles; if you must share, carefully clean needles and syringes with 
bleach between users. New, disposable needles should be used for tattooing, piercing, and 
acupuncture. Do not share personal items such as toothbrushes, razors, or manicure tools. 
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Cover all open cuts, sores, and rashes. Properly dispose of bandages, menstrual pads, 
tampons, and other material that comes into contact with blood or body fluids. Healthcare 
workers should exercise universal precautions such as wearing gloves and facial 
protection when working with blood and body fluids. 
Although many people previously contracted hepatitis through blood transfusions, 
donated blood has been tested for HBV since 1975 and for HCV since 1992. 
Transfusions are now considered quite safe. People do not get HBV or HCV from 
donating blood. 
HBV is found in semen and vaginal fluid, and is more likely than HCV to be transmitted 
through sexual activity. The CDC estimates that 30-60% of new HBV infections may be 
sexually transmitted. Use condoms or latex barriers such as dental dams to reduce the 
chances of sexual transmission. Pregnant women can transmit HBV to their infants 
during birth. The risk of perinatal transmission varies widely depending on the mother's 
HBV antigen status and viral load. It is recommended that all pregnant women be tested 
for HBV; if they have the virus, their infants can be vaccinated and given anti-HBV 
antibodies at birth. Although HBV antigens are found in breast milk, there is no evidence 
that breast feeding transmits the virus. 
HBV is present in saliva However, hepatitis B is not known to be transmitted by sharing 
silverware or drinking glasses, through sneezing or coughing, or by kissing. There are no 
documented cases of HBV transmission via urine, feces, sweat, tears, or vomit. As with 
hepatitis A, hepatitis B is sometimes spread through household contact with a person who 
carries the virus. People who immigrated or were adopted from areas with a high 
revalence of hepatitis B (e.g., Asia, sub-Saharan Africa, and the Middle East) and those 
4 
who travel to these areas for extended periods of time are also at higher risk. In as many 
as 30-40% of cases, the route ofHBV transmission is unknown. 
HBV is a relatively hardy virus; studies suggests that it can live in dried blood for up to 
ten days and on some surfaces for as long as 30 days. Carefully clean and disinfect any 
surfaces that come into contact with blood and other body fluids; a solution of one part 
bleach to ten parts water effectively kills HBV. 
1.4 Disease prevalence 
The management of hepatitis B virus (HBV) infection presents us with many challenges. 
Disease prevention, as well as supervision of chronic carriers of the infection, remains a 
key concern. Despite a rapid increase in the Expanded Program on Immunization (EPl) 
coverage, the global disease burden remains high. It is estimated that around 2 billion 
individuals worldwide have evidence of present or past infection with HBV. 
Approximately 350 million are chronic carriers of the virus, and it is expected that 
between 15% and 25% of them will die as a result of HBV. Disease progression can take 
up to 30 years; therefore an estimated 1 million individuals will die each year from 
chronic hepatitis, cirrhosis, or hepatocellular carcinoma. 
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1.4.1 High prevalence 
Globally, chronic hepatitis B (CHB) is widespread; approximately 45% of the global 
populations live in areas of high prevalence HBV. These areas include sub-Saharan 
Africa, aboriginal Australia, the East Mediterranean, South-east Asia (although 
Singapore, Taiwan and Malaysia are rapidly becoming areas of low/intermediate 
prevalence as a result of vaccination 1 ), South America, the Pacific Islands (excluding 
Japan), and the Inuit communities of Canada. It is expected that more than 8% of the 
population in these areas are positive to hepatitis B surface antigen (HBsAg). In high 
prevalence regions, the lifetime risk of HBV infection is greater than 60%, and most 
infections are acquired at birth or during early childhood when the risk of developing 
chronic infection is greatest. Because most infections in children are asymptomatic, very 
little acute disease related to HBV occurs, but rates of chronic liver disease and liver 
cancer in adults are very high. 
1.4.2 Intermediate prevalence 
Areas of intermediate prevalence include the countries that formed the old USSR, Eastern 
Europe, Japan, South-west Asia, Israel, and the Amazon Basin of South America. 
Approximately 43% of the global population live in areas of intermediate prevalence, 
with 2-7% of the population being hepatitis B surface antigen (HBsAg)-positive. The 
lifetime risk of being infected is 2~0% and infections occur in all age groups. Acute 
disease related to HBV is common because many infections occur in adolescents and 
adults; however, the high rates of chronic infection are maintained primarily by infections 
occurring in infants and children. 
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1.4.3 Low prevalence 
Only 12% of the populations live in areas with low prevalence and less than 2% of this 
population is HBsAg-positive. In low prevalence areas (e.g. North America, Canada, 
Mexico, Western Europe, Australia, and New Zealand [with the exception of the Maori 
population]), the lifetime risk of infection is less than 20%. Most HBV infections in these 
areas occur in adults in relatively well-defmed risk groups, including injecting drug users, 
homosexual men, and household contacts ofHBV carriers. 
1.5 Symptoms and Long-Term Effects 
HBV has an incubation period of 40-180 days. Acute (early) symptoms may include 
fever, nausea, vomiting, abdominal pain, loss of appetite (anorexia), itching (pruritis), 
muscle and joint aches, and fatigue. Some people also develop jaundice (yellowish 
discoloration of the skin and sclera), which is a sign that the liver is not properly 
processing bilirubin, a pigment released when old red blood cells are broken down; this 
may also lead to dark-colored urine and pale-colored stools. The acute symptoms of 
hepatitis B tend to be more severe than those of hepatitis C. 
However, 30-40% of people with acute hepatitis B have no symptoms. In a minority of 
cases, people with acute hepatitis B can develop severe or fatal fulminant liver 
inflammation; this is more likely in the elderly. Recovery from acute hepatitis usually 
takes 2-12 months, during this time a person may continue to experience fatigue and 
abdominal tenderness. Those who recover completely from hepatitis B are immune to 
HBVre-infection (although they can still contract hepatitis A and C). 
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Most people's immune systems clear HBV from their bodies, but some develop chronic 
hepatitis B (that is, the virus is still present after six months). HBV is much less likely 
than HCV to become chronic. Only 5-l 0% of people who are infected with HBV as 
adults develop chronic hepatitis B, compared to the 80-85% of HCV -infected people who 
develop chronic hepatitis C. The chances of developing chronic hepatitis B are much 
higher for infants or children; an estimated 80-90% of HBV -infected infants and 30-50% 
of HBV -infected children under age five develop chronic disease. Men are more likely 
than women to develop chronic hepatitis B. 
Symptoms of chronic hepatitis B may include persistent or intermittent fatigue, nausea, 
anorexia, and abdominal pain. Chronic carriers of inactive HBV often have no symptoms 
and normal laboratory tests, but they can still transmit the virus to others. 
Long-term effects of HBV infection are similar to those of chronic hepatitis C, including 
liver scarring (cirrhosis), fibrous deposits (fibrosis), primary liver cancer (hepatocellular 
carcinoma), and liver failure. It is estimated that 20-30% of people with chronic hepatitis 
B will go on to develop cirrhosis. Chronic hepatitis B tends to progress more rapidly than 
chronic hepatitis C. If liver damage progresses so far that the liver cannot carry out its 
essential functions, people may experience symptoms and related conditions including 
blood vessel damage, bleeding varicose veins in the esophagus or stomach, fluid in the 
abdomen (ascites), cognitive dysfunctio~ and coma. Severe liver failure may necessitate 
a liver transplant. HBV is responsible for estimated 5,000-6,000 deaths per year in the 
u.s. 
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1.6 Laboratory finding in HBV infection 
• Hepatitis B surface antigen (HBsAg) -- this represents the first viral marker 
present in blood tests after the patient is infected. It usually disappears from the 
blood in 1-2 months. 
• Hepatitis B core antibody (Anti-HBc) --this is usually detected within 1-2 weeks 
of the appearance of hepatitis B surface antigen. 
• Hepatitis B surface antibody (Anti-HBs) -- this is found both in those who have 
been immunized and those who have recovered from hepatitis infection. 
• Both hepatitis B surface antibody and core antibody persist indefinitely in the 
blood of patients who have recovered from hepatitis B. 
• Liver enzyme (transaminase) blood levels may be elevated due to liver damage. 
• Albumin levels may be low and prothrombin time may be prolonged due to 
severe liver failure. 
1.6.1 Hepatitis B virus (HBV) testing 
HBV is transmitted through infected body fluids, including blood, semen, and vaginal 
fluids (including menstrual blood). It is also can be transmitted from a pregnant woman 
to her child at or near the time of birth. 
• Hepatitis B surface antigen (HBsAg) is one of the most frequently performed tests 
for HBV. This HBV antigen is the earliest indicator of an active hepatitis B 
infection. This antigen may be present before symptoms appear. If this antigen 
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level remains high for more than 6 months, then you will probably become a 
carrier ofHBV, meaning you can transmit it to others throughout your life. 
• Hepatitis B surface antibody (HBsAb) is also one of the most common tests for 
HBV. Usually this antibody appears about 4 weeks after HBsAg disappears. This 
antibody also protects you from getting HBV again in the future. The test is done 
to determine the need for vaccination; the antibody is present in the body after 
vaccination. Occasionally your test may show that you have both the HBsAg and 
HBsAb; in this case, you are still contagious. 
• Hepatitis B core antigen (HBcAg). Currently, there is no test to find this antigen. 
• Hepatitis B core antibody (HBcAb) is an antibody to the hepatitis B core antigen. 
This antibody appears about 1 month after an active HBV infection. It can be 
found in people who had an infection in the past and in those with long-term 
(chronic) HBV. It usually is present for life. 
• Hepatitis B core antibody IgM (HBcAbigM) is also an antibody to the hepatitis B 
core antigen. It shows a recent infection in the last 6 months. 
• Hepatitis B e-antigen (HBeAg) is an HBV protein that is only present during an 
active HBV infection. This test determines how contagious you are. Testing for 
this antigen can also be used to monitor the effectiveness of treatment for HBV. 
• Hepatitis B e-antibody (HBeAb) shows that the active stage of the HBV infection 
is almost over and your risk of being contagious is greatly reduced. HBeAb is 
usually present during chronic HBV infections. 
HBV DNA testing fmds genetic material (DNA) from the hepatitis B virus. Currently, 
quantitative HBV DNA tests are done. A high HBV DNA level means that the virus is 
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multiplying in your body and you are very contagious. If you have a chronic HBV 
infection, an elevated viral DNA level means you are at an increased risk for chronic 
hepatitis and may be consider a treatment. Testing for HBV DNA also is important to 
monitor the effectiveness of treatment for chronic HBV infection. HBV DNA testing is a 
more sensitive test than HBeAg (above) for detecting HBV in the blood. 
/,.... 
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Figure 2: Progression to Chronic Hepatitis B Virus Infection Typical Serological 
Course 
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1. 7 Diagnosis of Hepatitis 
Hepatitis B is diagnosed and staged by looking at a complex combination ofHB-v 
antigens and antibodies in the blood. HBV has three antigens: HBsAg (surface), HBcAg 
(core), and HBeAg. The immune system produces three corresponding antibodies: anti-
HBs, anti-HBc, and anti-HBe. The presence of HBsAg in the blood indicates that a 
person currently has hepatitis B-which may be either active or inactive (carrier state) -
and can transmit the disease to others. The presence of HBeAg indicates that HBV is 
actively replicating and that a person is highly infectious and at greater risk for liver 
damage. The presence of anti-HBs antibodies in the absence of HBsAg shows that a 
person was previously infected with HBV but has recovered; they no longer have active 
disease, cannot transmit the virus, and are now immune (most people who have received 
the HBV vaccine have anti-HBs antibodies). 
Today there are tests that directly measure HBV DNA (genetic material) rather 
than antigens and antibodies. Two common tests are the polymerase chain reaction (PCR) 
and branched DNA (bONA) assays; others are being developed A detectable viral load 
indicates that the virus is actively replicating; asymptomatic HBV carriers may shown 
little or no evidence of HBV replication. In addition to determining the presence ofHBV, 
viral load tests are also used to monitor how well treatment is working. 
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1.8 HBV Coinfection 
Because HBV and HCV are transmitted by similar means, some people 
(especially injection drug users) are infected with both viruses. Coinfection refers to 
simultaneous infection with HBV and HCV, while super infection refers to a person 
getting the second virus after they have already been infected with the first one. Research 
indicates that coinfection and super infection can lead to more serious liver damage than 
infection with either HBV or HCV alone. Affected people are at higher risk for liver 
cancer and for fulminant hepatitis, a serious acute inflammation that can result in rapid 
liver damage. Some studies suggest that even people who have recovered from hepatitis 
B may be more likely to develop cirrhosis and primary liver cancer if they later contract 
HCV. Because dual infection can lead to more severe liver disease, people with HCV 
should ask their doctor about getting vaccinated against hepatitis B and hepatitis A. 
1.9 Vaccination 
Unlike hepatitis C, hepatitis B can be prevented with a vaccine. There are 
currently two HBV vaccines, SmithKline Beecham's Energix-B and Merck's 
Recombivax HB. The vaccine is typically administered as a series of three intramuscular 
injections given over six months (the second injection one month after the first, and the 
third injection five months later). If the series is not completed within six months, it is 
necessary to start over. An alternate 2-dose vaccine schedule has been FDA-approved for 
adolescents aged 11-15. The HBV vaccine is now recommended as part of the standard 
childhood vaccination series, and for adolescents who were not vaccinated as children. 
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It is also recommended for (among others) injection drug users, health care 
workers, sexually active adults, and household contacts of HBV carriers. In May 2001, 
the FDA approved a new combined hepatitis A/hepatitis B vaccine (Twinrix). 
If a person has recently been exposed to HBV, post exposure prophylaxis using 
immune globulin (injected antibodies) can help prevent a person from developing 
hepatitis B or reduce the length and severity of illness. This procedure, known as passive 
immunizatio~ is effective about 75% of the time. Anti-HB V immune globulin (Hl:HG) 
should be given within 72 hours after exposure. HBIG can also help prevent the 
transmission of the HBV from a pregnant woman to her baby if given within 12 hours 
after birth. Because immune globulin only confers temporary protection (about three 
months), it is typically administered along with the first dose of the HBV vaccine. 
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1.10 Objectives 
1. To measure the important ofHB Core Ag as a screening tool. 
u. To detect HB Core Ag among blood donors. 
111. To compare specificity and sensitivity of tests to Hepatitis B virus. 
tv. To identify the prevalence of hepatitis B among blood donors. 
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